Myasthenia Gravis Market by Treatment, Geography and Forecast to 2027 - TMR

According to Transparency Market Research’s latest report on the global myasthenia gravis market for the historical period 2018–2019 and forecast period 2020–2030, high prevalence of autoimmune diseases and strong focus on introducing new therapies is augmenting the growth of global myasthenia gravis market. Moreover, improving healthcare infrastructure is likely boost the growth of global myasthenia gravis market during the forecast period.
According to the report, the global myasthenia gravis market was valued at US$ 1.2 Bn in 2018 and is anticipated to expand at a CAGR of 8.0% from 2019 to 2027

Autoimmune disorder is a condition of immune system in which the body's immune system attacks healthy cells. It is most common in the older men (over 60) and young adult women (under 40). Hence, increase in geriatric population is a key factor likely boost the growth of market. For instance, according to Cancer Facts & Figures 2019, estimated number of older adults age 85 years and above was 6.4 million in 2016 and it is expected to reach 19.0 million by 2060
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that affects voluntary muscles. According to the Myasthenia Gravis Foundation of America, around 20 in 100,000 people in the U.S. are diagnosed with myasthenia gravis each year
Myasthenia gravis is a rare disease without a definite cure, however it can be treated with medications, surgeries, and other therapies alone or in combination. This is augmenting the demand for new therapies and medications, which is driving key players operating in the market to invest in the research and development and develop new therapies. For instance, Rozanolixizumab (UCB7665) is a humanized anti-human neonatal Fc receptor (FcRn) monoclonal antibody designed to reduce the levels of pathogenic IgG in autoimmune diseases. It is in clinical trial phase for reducing the levels of pathogenic IgG in autoimmune diseases and myasthenia gravis. Strong pipeline and introduction of new therapies are the factors likely boost the growth of myasthenia gravis market

Expanding operations in future? To get the perfect launch ask for a custom report

Increase in health care expenditure coupled with rise in global per capita income is anticipated to drive demand for costly treatments such as plasma exchange and intravenous immunoglobulin (IVIG) therapies
Moreover, governments in developing countries are making significant investments toward modernization of health care infrastructure, which is likely to increase access to health care. This is expected to increase in the demand for advance technologies, therapies and treatments. This is leading to create opportunities in the monoclonal antibodies and IVIG treatments in the myasthenia gravis market in the near future

Discovery and development of new therapeutics incurs high cost and takes longer time for commercialization. The never approved therapies with IVIG and monoclonal antibodies are expensive treatment options. The cost of plasma collection and manufacturing processes for IVIG products is high as compared to the materials and processes used in the manufacture of traditional pharmaceutical products. Moreover, being a blood derived component, highly sophisticated collection, purification, and storage methods are required for intravenous immunoglobulin (IVIG) products.
Plasmapheresis and thymectomy are costly in comparison to symptomatic drug therapy which additionally need hospitalization. Cost is major factor that influence the selection of treatment which is anticipated to hamper the growth of global myasthenia gravis treatment market.

Side effects associated with intravenous immunoglobulin (IVIG) preparations could present serious health problems in some patients. Some of the side effects associated with intravenous immunoglobulin (IVIG) are flushing, muscle cramps, chills, fever, nausea, vomiting, back/joint pain, chest pain, sudden cough, wheezing, or shortness of breath.
These side effects can sometimes force a patient to discontinue the therapy which are leading to restrain the global myasthenia gravis market.

This report profiles major players in the global myasthenia gravis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global myasthenia gravis market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global myasthenia gravis market are